The DNA Polymerase Gamma R953C Mutant Is Associated with Antiretroviral Therapy-Induced Mitochondrial Toxicity

ABSTRACT We found a heterozygous C2857T mutation (R953C) in polymerase gamma (Pol-γ) in an HIV-infected patient with mitochondrial toxicity. The R953C Pol-γ mutant binding affinity for dCTP is 8-fold less than that of the wild type. The R953C mutant shows a 4-fold decrease in discrimination of analog nucleotides relative to the wild type. R953 is located on the “O-helix” that forms the substrate deoxynucleoside triphosphate (dNTP) binding site; the interactions of R953 with E1056 and Y986 may stabilize the O-helix and affect polymerase activity.

[1]  Shanmugapriya Selvaraj,et al.  Antiretroviral therapy–induced toxicity is associated with increased mRNA expression of telomerase , 2015, Journal of clinical pharmacology.

[2]  Shanmugapriya Selvaraj,et al.  Antiretroviral Therapy-Induced Mitochondrial Toxicity: Potential Mechanisms Beyond Polymerase-γ Inhibition , 2014, Clinical pharmacology and therapeutics.

[3]  K. Anderson,et al.  Mutations in human DNA polymerase γ confer unique mechanisms of catalytic deficiency that mirror the disease severity in mitochondrial disorder patients. , 2013, Human molecular genetics.

[4]  S. Dimauro,et al.  POLG1 Arg953Cys mutation: Expanded phenotype and recessive inheritance in a Brazilian family , 2012, Muscle & nerve.

[5]  M. Milone,et al.  Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)-like phenotype: an expanded clinical spectrum of POLG1 mutations , 2012, Journal of Neurology.

[6]  W. Craigen,et al.  Mitochondrial DNA polymerase γ mutations: an ever expanding molecular and clinical spectrum , 2011, Journal of Medical Genetics.

[7]  Christopher M. Bailey,et al.  R964C Mutation of DNA Polymerase γ Imparts Increased Stavudine Toxicity by Decreasing Nucleoside Analog Discrimination and Impairing Polymerase Activity , 2009, Antimicrobial Agents and Chemotherapy.

[8]  B. Debuire,et al.  Relationship between polymerase gamma (POLG) polymorphisms and antiretroviral therapy-induced lipodystrophy in HIV-1 infected patients: a case-control study. , 2009, Current HIV research.

[9]  Minhee Kang,et al.  Increased mtDNA Levels Without Change in Mitochondrial Enzymes in Peripheral Blood Mononuclear Cells of Infants Born to HIV-Infected Mothers on Antiretroviral Therapy , 2008, HIV clinical trials.

[10]  S. Oka,et al.  Novel mutation of human DNA polymerase gamma associated with mitochondrial toxicity induced by anti-HIV treatment. , 2007, The Journal of infectious diseases.

[11]  Robert W. Taylor,et al.  Phenotypic spectrum associated with mutations of the mitochondrial polymerase γ gene. Commentary , 2006 .

[12]  Robert W. Taylor,et al.  Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene. , 2006, Brain : a journal of neurology.

[13]  W. Copeland,et al.  Consequences of mutations in human DNA polymerase γ , 2005 .

[14]  M. Zeviani,et al.  Infantile hepatocerebral syndromes associated with mutations in the mitochondrial DNA polymerase-gammaA. , 2005, Brain : a journal of neurology.

[15]  W. Copeland,et al.  Consequences of mutations in human DNA polymerase gamma. , 2005, Gene.

[16]  G. Węgrzyn,et al.  A modified procedure for quantitative analysis of mtDNA, detecting mtDNA depletion. , 2005, Journal of applied genetics.

[17]  L. Peltonen,et al.  Parkinsonism, premature menopause, and mitochondrial DNA polymerase γ mutations: clinical and molecular genetic study , 2004, The Lancet.

[18]  L. Kaguni.  DNA Polymerase γ, The Mitochondrial Replicase1 , 2004 .

[19]  L. Kaguni.  DNA polymerase gamma, the mitochondrial replicase. , 2004, Annual review of biochemistry.

[20]  W. Copeland,et al.  Structural determinants in human DNA polymerase gamma account for mitochondrial toxicity from nucleoside analogs. , 2003, Journal of molecular biology.

[21]  B. Gazzard,et al.  Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors , 2002, AIDS.

[22]  G. Moyle.  Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. , 2000, Clinical therapeutics.

[23]  T. Kakuda,et al.  Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. , 2000, Clinical therapeutics.

[24]  J. Smeitink,et al.  Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway , 1998, AIDS.

[25]  M. Dalakas,et al.  Mitochondrial toxicity of antiviral drugs , 1995, Nature Medicine.